BOEHRINGER-INGELHEIM
Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced a new multi-year partnership to conduct collaborative research to rapidly advance therapies for various types of cancers, including gastrointestinal and lung cancers. The establishment of a joint Virtual Research and Development Center will enable effective data sharing and analysis between the organizations.
The partnership is built on a flexible framework, allowing for projects to enter at different stages (research, development and/or clinical stage) over several years. It further combines the unique patient-driven drug-development capabilities of MD Anderson’s Therapeutics Discovery division with the innovative pipeline of novel medicines from Boehringer Ingelheim.
MD Anderson’s Therapeutics Discovery division is a multidisciplinary team of clinicians and researchers focused on advancing the next generation of cancer therapies. As part of the division, the TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology) platform conducts cutting-edge translational research to better understand how new medicines work and which patients will see most benefit.
"We could not have chosen a better partner with all its research, translational and clinical expertise in lung and gastrointestinal cancers. Together, we hope to transform the treatment landscape for these diseases by tackling their root causes and drivers, that have so far remained elusive, exploring new and smart ways of killing cancer cells," said Dr Victoria Zazulina, Corporate Vice President and Global Head of Oncology, Medicine, at Boehringer Ingelheim. "Our innovative oncology pipeline coupled with strong partnerships like this will contribute to unravelling the complexities of these diseases and bringing innovative solutions to people with various types of cancers."
The Virtual Research and Development Center will focus on the development of potential new treatments including:
- KRAS inhibition concepts, as mutations in the KRAS gene are common in various cancers, specifically in certain types of lung and gastrointestinal cancers.
- a TRAILR2 agonistic antibody, with the potential to selectively induce cancer cell death (apoptosis).
“Within MD Anderson, we are committed to a singular goal of ending cancer,” said Tim Heffernan, Ph.D., executive director of TRACTION at MD Anderson. “We look forward to working with Boehringer Ingelheim to advance their innovative pipeline of cancer medicines. Our Therapeutics Discovery team is well-poised to conduct impactful translational research, and this partnership will allow us to more rapidly advance much-needed new therapies to patients.”
More than 4.1 million people die from gastrointestinal and lung cancers every year worldwide1 , indicating an urgent need for new treatment approaches. Gastrointestinal cancers represent a heterogeneous complex array of diseases, and include oesophageal (throat), gastric (stomach), liver, pancreatic, and colorectal cancers. In 2018, lung cancer caused more than 1.7 million deaths1 . There are two main types of lung cancer: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
Please click on the link for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/press-release/boehringer-ingelheim-and-md-anderson-form-collaboration
For more information, visit:
https://www.boehringer-ingelheim.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190812005307/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SFI Health™ Reports Promising Results From a Preliminary Study Evaluating the Impact of Long-Chain Polyunsaturated Fatty Acids on Reading and Writing Skills in Children27.11.2025 08:15:00 CET | Press release
- The study sponsored by La Nostra Famiglia highlights key brain processes that mediate the effects of omega-3s on literacy development- Further research into the biological mechanisms explaining the effects of omega-3 LCPUFAs on neurocognitive structures and functions is needed to open new pathways for intervention in learning disorders SFI Health™ EMEA, the regional entity of SFI Health™, a global leader in natural healthcare, is proud to announce the publication on Biomedicine of the results of a new study, conducted by the Italian research institute “IRCCS Eugenio Medea” of “La Nostra Famiglia” association, investigating the correlation between long-chain polyunsaturated fatty acids (LCPUFA) and reading and writing abilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251126097656/en/ Italian Research Institute "IRCCS Eugenio Medea" of "La Nostra Famiglia". This investigator-initiated trial is part of an ongoing proj
JPMorganChase Announces Intention to Build a New Three-Million Sq Ft Landmark Tower in London27.11.2025 07:00:00 CET | Press release
Including the cost of construction, the project could contribute £9.9 billion ($13 billion) over six years to the local economy, including an additional 7,800 jobs across construction and other local industriesThe new building would house up to 12,000 people and serve as the firm’s principal headquarters in the UK and its most significant presence in Europe, the Middle East and Africa (EMEA). JPMorganChase is a major employer in the UK with 23,000 employees there in totalJPMorganChase already contributes nearly £7.5 billion ($9.8 billion) annually to the local economy, supporting 38,000 jobs across surrounding industriesThe building would be one of the largest and most sophisticated in Europe with more than three-million square feet (Gross Internal Area) of space, reinforcing London’s status as a leading financial centre on the global stagePlans are subject to a continuing positive business environment in the UK and the firm receiving the necessary approvals and agreementsIn addition t
WattCycle Unveils 2025 Black Friday Battery Sales with Europe-Wide Savings on LiFePO4 Batteries27.11.2025 07:00:00 CET | Press release
WattCycle today announces the launch of its Europe-wide Black Friday battery deals 2025, offer up to 60% off for LiFePO4 batteries plus an additional 8% discount at checkout with no minimum order value. All EU users are covered by 30 days price protection policy to ensure they secure the best available price during the promotion. Get your Battery Coupon Code: BlackFriday8% Of particular note is the WattCycle 12V 314Ah battery, featured as the most heavily discounted product in the 2025 Black Friday sales. The battery is offered at €489,99 (was €1.299,99), representing a 60% discount. After using the "BlackFriday8%" battery coupon code only €450.79. This battery delivers 4.019Wh of usable energy and engineered with advanced 200A BMS and EV A+ Grade cells rated for 15.000+ cycles, offering a reliable long-term power solution for diverse applications. WattCycle Marine Solution The European boating season underscores the need for dependable, lightweight power. WattCycle 12V 100Ah TM Blueto
Vietnam’s C4IR and Ant International Partner to Accelerate Innovation as Ho Chi Minh City Eyes Becoming International Financial Centre27.11.2025 04:46:00 CET | Press release
Ant International will be recognised as an Official Partner of the HCM City government, strengthening public-private collaboration to drive long-term sustainable growthHCM City, C4IR and Ant International will work together comprehensively across empowering SMEs, globalising the local digital economy, implementing emerging technologies, cultivating joint innovation and developing talent The Vietnam Centre for the Fourth Industrial Revolution (C4IR Vietnam), established by the World Economic Forum and the People’s Committee of Ho Chi Minh City, and Ant International today announced a strategic partnership through a Memorandum of Understanding (MoU) to advance Vietnam’s digital economy, foster innovation, and support Ho Chi Minh City’s (HCMC) ambition to become an international financial centre and regional fintech hub. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251126280083/en/ The partnership was announced at the Ho Chi
LambdaTest and SVAM International Inc. Announce Partnership to Transform Quality Engineering for Businesses26.11.2025 18:00:00 CET | Press release
The alliance empowers enterprises with accelerated SDLC cycles, reduced testing effort, and modern AI-driven digital transformation capabilities LambdaTest, a Gen-AI native quality engineering platform, announced a partnership with SVAM International, Inc., a global leader in digital transformation services. This strategic alliance marks a significant step forward in their mission to transform quality engineering for businesses worldwide. The partnership allows LambdaTest to extend its AI-native quality engineering capabilities into SVAM’s extensive digital transformation ecosystem. By integrating with SVAM’s experience in large-scale application development, testing, and delivery across major New York State and City agencies, as well as their platform expertise across Salesforce, ServiceNow, and Dynamics365, LambdaTest will empower more enterprises to modernize their software delivery pipelines. With LambdaTest’s intelligent test orchestration and execution engine at the core, teams c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom